AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7512356 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG-CSF
Number of subjects: 46
Study 7512356 — intervention group
Group type: COMPARATOR
Intervention: Control (no rhG-CSF)
Number of subjects: 46
Study 7512356 — intervention group
Group type: EXPERIMENTAL
Intervention: VM-26 dose levels (60, 80, 100, 120 mg/m2/day)
Number of subjects: 46
Study 7512356 — intervention group
Group type: EXPERIMENTAL
Intervention: VM-26 plus CDDP with rhG-CSF
Number of subjects: 46
Study 7512356 — intervention group
Group type: EXPERIMENTAL
Intervention: VM-26 dose level of 120 mg/m2/day
Number of subjects: 46
Study 7512356 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 46
Study 2893038 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of single-strand recombinant tissue plasminogen activator (rTPA) in 3 hours (n = 73)
Number of subjects: 144
Study 2893038 — intervention group
Group type: COMPARATOR
Intervention: Placebo infused at the same rate (n = 71)
Number of subjects: 144
Study 2893038 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of single-strand recombinant tissue plasminogen activator (rTPA)
Number of subjects: 144
Study 2893038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 29504252 — intervention group
Group type: EXPERIMENTAL
Intervention: AZL-M/CLD 20/12.5 mg
Number of subjects: 153
Study 29504252 — intervention group
Group type: COMPARATOR
Intervention: OLM/HCTZ 20/12.5 mg
Number of subjects: 153
Study 29504252 — intervention group
Group type: EXPERIMENTAL
Intervention: AZL-M/CLD
Number of subjects: 153
Study 29504252 — intervention group
Group type: COMPARATOR
Intervention: OLM/HCTZ
Number of subjects: 153
Study 27160461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined computed tomography (CT)‐based and image‐free navigation system
Number of subjects: 62
Study 27160461 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 62
Study 27160461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CT-based navigation
Number of subjects: 62
Study 25699397 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DCRT+HT (three-dimensional conformal radiotherapy combined with abdominal hyperthermia)
Number of subjects: 68
Study 25699397 — intervention group
Group type: COMPARATOR
Intervention: 3DCRT (three-dimensional conformal radiation therapy)
Number of subjects: 68
Study 22374557 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-based counseling using a behavioral approach (n=119)
Number of subjects: 235
Study 22374557 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 235
Study 22374557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (men)
Number of subjects: 235
Study 22374557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (women)
Number of subjects: 235
Study 22374557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (both genders)
Number of subjects: 235
Study 22374557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 235
Study 22374557 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants maintaining action/maintenance stage
Number of subjects: 235
Study 20609025 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon filled with immediate post space preparation leaving 5 mm of apical filling
Number of subjects: 150
Study 20609025 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon filled with delayed post space preparation for 1 week leaving 5 mm of material apically
Number of subjects: 150
Study 20609025 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon filled with immediate post space preparation leaving 3 mm of material apically
Number of subjects: 150
Study 20609025 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon filled with delayed post space preparation for 1 week leaving 3 mm of material apically
Number of subjects: 150
Study 20609025 — intervention group
Group type: COMPARATOR
Intervention: Control group (root canals not filled)
Number of subjects: 150
Study 17591530 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdialytic weight gain (IDWG)
Number of subjects: 442
Study 16046102 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 mg SAMe (pharmaceutical dose)
Number of subjects: 12
Study 16046102 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg SAMe (nutraceutical dose)
Number of subjects: 12
Study 16046102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12122721 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin 14 (S-14) infusion at a dose of 6 mg/24 h (days 1-6) and 3 mg/24 h (day 7)
Number of subjects: 75
Study 12122721 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 75
Study 11016491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic cardiomyoplasty
Number of subjects: 0
Study 11016491 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 0
Study 8646833 — intervention group
Group type: EXPERIMENTAL
Intervention: DIABETES expert system for decision support
Number of subjects: 600
Study 8646833 — intervention group
Group type: COMPARATOR
Intervention: Medical doctors' responses
Number of subjects: 600
Study 1498074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential MTX (300 mg/m2) and FU (900 mg/m2) with leucovorin rescue
Number of subjects: 172
Study 1498074 — intervention group
Group type: COMPARATOR
Intervention: FU alone (450 mg/m2/d for five days)
Number of subjects: 172
Study 1498074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential MTX/FU
Number of subjects: 172
Study 1498074 — intervention group
Group type: COMPARATOR
Intervention: FU alone
Number of subjects: 172
Study 1498074 — intervention group
Group type: COMPARATOR
Intervention: Sequential MTX/FU and FU alone
Number of subjects: 172
Study 6395272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid
Number of subjects: 1060
Study 30943313 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 22
Study 28065207 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging follow-up (40 participants)
Number of subjects: 118
Study 28065207 — intervention group
Group type: COMPARATOR
Intervention: Conventional telephone follow-up (78 participants)
Number of subjects: 118
Study 26871794 — intervention group
Group type: EXPERIMENTAL
Intervention: F4/AS01B_2 group (N=64)
Number of subjects: 186
Study 26871794 — intervention group
Group type: EXPERIMENTAL
Intervention: F4/AS01B_3 group (N=62)
Number of subjects: 186
Study 26871794 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=64)
Number of subjects: 186
Study 26871794 — intervention group
Group type: EXPERIMENTAL
Intervention: F4/AS01B
Number of subjects: 186
Study 25135040 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation (TVNS) applied to the auricular concha bilaterally for 35min using 2Hz/100Hz bursts with individually maximal but non-painful intensity
Number of subjects: 22
Study 25135040 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no stimulation)
Number of subjects: 22
Study 25135040 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation (TVNS)
Number of subjects: 22
Study 22314130 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 636
Study 22314130 — intervention group
Group type: COMPARATOR
Intervention: Surgical repair
Number of subjects: 636
Study 19171289 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 155
Study 19171289 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio
Number of subjects: 155
Study 17198906 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 1123
Study 17198906 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren monotherapy
Number of subjects: 1123
Study 17198906 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren and valsartan in combination
Number of subjects: 1123
Study 17198906 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/hydrochlorothiazide (160/12.5 mg)
Number of subjects: 1123
Study 17198906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1123
Study 16246660 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG‐20 microg IUS
Number of subjects: 320
Study 16246660 — intervention group
Group type: COMPARATOR
Intervention: Cu T380A IUD
Number of subjects: 320
Study 11565518 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 to 100 mg once daily)
Number of subjects: 1513
Study 11565518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study 9280384 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Skills Training program (BST; Wurtele, 1986)
Number of subjects: 406
Study 9280384 — intervention group
Group type: COMPARATOR
Intervention: Control program
Number of subjects: 406
Study 8336206 — intervention group
Group type: EXPERIMENTAL
Intervention: 7500 micrograms RE (Group B)
Number of subjects: 149
Study 8336206 — intervention group
Group type: EXPERIMENTAL
Intervention: 60,000 micrograms RE (Group C)
Number of subjects: 149
Study 8336206 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oil only (Group A)
Number of subjects: 149
Study 3464712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam
Number of subjects: 50
Study 3464712 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam
Number of subjects: 50
Study 2732067 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Rs and HBP curriculum with home blood pressure measurement component
Number of subjects: 1204
Study 2732067 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Rs and HBP curriculum without home blood pressure measurement component
Number of subjects: 1204
Study 2732067 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1204
Study 31816193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-rapid lispro (URLi)
Number of subjects: 31
Study 31816193 — intervention group
Group type: COMPARATOR
Intervention: lispro (Humalog®)
Number of subjects: 31
Study 31816193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-rapid lispro (URLi) and lispro (Humalog®)
Number of subjects: 31
Study 31154239 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional group therapy plus an additional 10 hours of group therapy focusing on stimulant use
Number of subjects: 108
Study 31154239 — intervention group
Group type: COMPARATOR
Intervention: Conventional group therapy only (treatment as usual)
Number of subjects: 108
Study 28334419 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT) with good/excellent cosmetic outcomes
Number of subjects: 128
Study 28334419 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT) with fair/poor cosmetic outcomes
Number of subjects: 128
Study 28334419 — intervention group
Group type: EXPERIMENTAL
Intervention: BCCT.core software evaluation
Number of subjects: 128
Study 25033034 — intervention group
Group type: EXPERIMENTAL
Intervention: CogSMART intervention
Number of subjects: 50
Study 25033034 — intervention group
Group type: COMPARATOR
Intervention: Additional supported employment sessions
Number of subjects: 50
Study 23490168 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐Seed personal lubricant
Number of subjects: 22
Study 23490168 — intervention group
Group type: COMPARATOR
Intervention: No lubricant (control)
Number of subjects: 22
Study 21464685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (12 weekly healthy lifestyle sessions based on the Diabetes Prevention Program curriculum)
Number of subjects: 45
Study 21464685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 45
Study 21464685 — intervention group
Group type: COMPARATOR
Intervention: Wait control group
Number of subjects: 45
Study 18317875 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (ARB)
Number of subjects: 13
Study 18317875 — intervention group
Group type: COMPARATOR
Intervention: Control (no ARB)
Number of subjects: 13
Study 16099450 — intervention group
Group type: EXPERIMENTAL
Intervention: Home remediation
Number of subjects: 98
Study 15519938 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-stroke back massage (SSBM) for ten minutes for seven consecutive evenings
Number of subjects: 102
Study 15519938 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-stroke back massage (SSBM)
Number of subjects: 102
Study 11764128 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose Plus with Z‐100
Number of subjects: 20
Study 11764128 — intervention group
Group type: COMPARATOR
Intervention: 5% NaOCl treatment after phosphoric acid treatment
Number of subjects: 20
Study 11764128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavities treated without NaOCl
Number of subjects: 20
Study 11764128 — intervention group
Group type: COMPARATOR
Intervention: Cavities treated with NaOCl
Number of subjects: 20
Study 9284856 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (200 mg/day)
Number of subjects: 40
Study 9284856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8329783 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg with 6‐minute lockout (n = 10)
Number of subjects: 34
Study 8329783 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg with 12‐minute lockout (n = 12)
Number of subjects: 34
Study 8329783 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg with 20‐minute lockout (n = 12)
Number of subjects: 34
Study 8329783 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 34
Study 3771502 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10
Study 3771502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31578100 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 633
Study 31578100 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA administered by a specialist nurse
Number of subjects: 633
Study 31578100 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA with removal of the positive stopping rule
Number of subjects: 633
Study 31578100 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of onabotulinumtoxinA scenarios
Number of subjects: 633
Study 31578100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study 31176028 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled-dose multimodal analgesia with minimal opiate supply (group A)
Number of subjects: 235
Study 31176028 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled-dose multimodal analgesia with traditional opiate supply (group B)
Number of subjects: 235
Study 31176028 — intervention group
Group type: COMPARATOR
Intervention: Traditional pro re nata (as needed) opiate regimen alone (group C)
Number of subjects: 235
Study 28961661 — intervention group
Group type: EXPERIMENTAL
Intervention: Blister packing medications (BP)
Number of subjects: 243
Study 28961661 — intervention group
Group type: COMPARATOR
Intervention: Dispense as usual (Control)
Number of subjects: 243
Study 26165588 — intervention group
Group type: COMPARATOR
Intervention: Baseline prostate atrophy (graded as absent, mild, or moderate/marked)
Number of subjects: 3084
Study 26165588 — intervention group
Group type: COMPARATOR
Intervention: Mild atrophy
Number of subjects: 3084
Study 26165588 — intervention group
Group type: COMPARATOR
Intervention: Moderate/marked atrophy
Number of subjects: 3084
Study 26165588 — intervention group
Group type: COMPARATOR
Intervention: Baseline prostate atrophy
Number of subjects: 3084
Study 22781166 — intervention group
Group type: EXPERIMENTAL
Intervention: Full cognitive behaviour therapy (CBT)
Number of subjects: 92
Study 22781166 — intervention group
Group type: COMPARATOR
Intervention: Partial therapy (attending sessions but not proceeding beyond engagement and assessment strategies)
Number of subjects: 92
Study 22781166 — intervention group
Group type: COMPARATOR
Intervention: No therapy (not attending sessions)
Number of subjects: 92
Study 21780853 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide plus metformin 1 mg/500 mg t.i.d. (maximum dose, 4 mg/500 mg t.i.d.)
Number of subjects: 432
Study 21780853 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide 1 mg t.i.d. (maximum dose, 4 mg t.i.d.)
Number of subjects: 432
Study 21780853 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide plus metformin
Number of subjects: 432
Study 21780853 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide
Number of subjects: 432
Study 18582181 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.4 mg/kg)
Number of subjects: 11
Study 18582181 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.8 mg/kg)
Number of subjects: 11
Study 18582181 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (1.5 mg/kg)
Number of subjects: 11
Study 18582181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 17090999 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose
Number of subjects: 60
Study 17090999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17090999 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 12646783 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute inflammatory events (IE) in the previous 30 days
Number of subjects: 293
Study 12646783 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute inflammatory events (IE) in the previous 7 days
Number of subjects: 293
Study 12646783 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute inflammatory events (IE) stratified for atherothrombotic stroke
Number of subjects: 293
Study 12646783 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute inflammatory events (IE) stratified for cardioembolic stroke
Number of subjects: 293
Study 11388814 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal CPAP (n = 29)
Number of subjects: 55
Study 11388814 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP (n = 25)
Number of subjects: 55
Study 9094765 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-week aerobic activity program, exercised 4 days per week
Number of subjects: 25
Study 9094765 — intervention group
Group type: COMPARATOR
Intervention: Regular physical education program (control group)
Number of subjects: 25
Study 8325074 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygroscopic heat and moisture exchangers (groups 2 and 3)
Number of subjects: 0
Study 8325074 — intervention group
Group type: COMPARATOR
Intervention: Hydrophobic heat and moisture exchanger (group 1)
Number of subjects: 0
Study 2880689 — intervention group
Group type: EXPERIMENTAL
Intervention: Indenolol (30 to 120 mg)
Number of subjects: 19
Study 30889454 — intervention group
Group type: EXPERIMENTAL
Intervention: CurQfen® (curcumin formulated with fenugreek soluble fiber) at 500mg/d for 12 weeks
Number of subjects: 22
Study 30889454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fenugreek soluble fiber)
Number of subjects: 22
Study 28397533 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy adherence assessment
Number of subjects: 242
Study 28397533 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic factors (income and ethnicity)
Number of subjects: 242
Study 25990260 — intervention group
Group type: COMPARATOR
Intervention: 980-nm laser
Number of subjects: 96
Study 25990260 — intervention group
Group type: EXPERIMENTAL
Intervention: 1470-nm laser
Number of subjects: 96
Study 24475556 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% gentian violet paint local application
Number of subjects: 400
Study 24475556 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 400
Study 25155813 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9
Number of subjects: 172
Study 25155813 — intervention group
Group type: EXPERIMENTAL
Intervention: BDI-II
Number of subjects: 172
Study 25155813 — intervention group
Group type: COMPARATOR
Intervention: PHQ-9 and BDI-II
Number of subjects: 172
Study 18426627 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral administration of ramosetron 0.1 mg (Group C)
Number of subjects: 240
Study 18426627 — intervention group
Group type: EXPERIMENTAL
Intervention: Single prophylactic intravenous injection of ramosetron 0.1 mg (Group B)
Number of subjects: 240
Study 18426627 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antiemetics (Group A)
Number of subjects: 240
Study 17175489 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 0.2 mg/day (Group 1)
Number of subjects: 58
Study 17175489 — intervention group
Group type: COMPARATOR
Intervention: Cetrorelix 0.15 mg/day (Group 2)
Number of subjects: 58
Study 14561020 — intervention group
Group type: EXPERIMENTAL
Intervention: HandiHaler (tiotropium 18 microg daily)
Number of subjects: 151
Study 14561020 — intervention group
Group type: COMPARATOR
Intervention: MDI (ipratropium 20 microg, two actuations q.i.d.)
Number of subjects: 151
Study 14561020 — intervention group
Group type: EXPERIMENTAL
Intervention: HandiHaler
Number of subjects: 151
Study 14561020 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 151
Study 11127249 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (oral dose)
Number of subjects: 17
Study 8865956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU three times a week)
Number of subjects: 59
Study 8865956 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological markers of alcohol consumption
Number of subjects: 59
Study 8865956 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate deficient transferrin
Number of subjects: 59
Study 8865956 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase
Number of subjects: 59
Study 8865956 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase
Number of subjects: 59
Study 8865956 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma‐glutamyl transpeptidase
Number of subjects: 59
Study 8865956 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐hexosaminidase
Number of subjects: 59
Study 1893708 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 380A
Number of subjects: 2845
Study 1893708 — intervention group
Group type: EXPERIMENTAL
Intervention: LLD
Number of subjects: 2845
Study 1893708 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu 375
Number of subjects: 2845